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Nitric oxide (NO) plays an important role in the control of the vascular tone and the most often employed
NO donors have limitations due to their harmful side-effects. In this context, new NO donors have been
prepared, in order to minimize such undesirable effects. cis-[Ru(bpy)2(py)NO2](PF6) (RuBPY) is a new
nitrite complex synthesized in our laboratory that releases NO in the presence of the vascular tissue only.
In this work the vasorelaxation induced by this NO donor has been studied and compared to that
obtained with the well known NO donor SNP. The relaxation induced by RuBPY is concentration-depen-
dent in denuded rat aortas pre-contracted with phenylephrine (EC50). This new compound induced relax-
ation with efﬁcacy similar to that of SNP, although its potency is lower. The time elapsed until maximum
relaxation is achieved (Emax = 240 s) is similar to measured for SNP (210 s). Vascular reactivity experi-
ments demonstrated that aortic relaxation by RuBPY is inhibited by the soluble guanylyl-cyclase inhibitor
1H-[1,2,4] oxadiozolo[4,3-a]quinoxaline-1-one (ODQ 1 lM). In a similar way, 1 lM ODQ also reduces NO
release from the complex as measured with DAF-2 DA by confocal microscopy. These ﬁndings suggest
that this new complex RuBPY that has nitrite in its structure releases NO inside the vascular smooth mus-
cle cell. This ruthenium complex releases signiﬁcant amounts of NO only in the presence of the aortic tis-
sue. Reduction of nitrite to NO is most probably dependent on the soluble guanylyl-cyclase enzyme, since
NO release is inhibited by ODQ.
 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
The endogenous production of nitric oxide (NO) is a key step in
the control of the vascular tone [1]. Moreover, it plays an important
role in a variety of physiological and pathological processes such as
neurotransmission, blood pressure control, inhibition of platelet
aggregation, and immunological responses in different cells and
tissues [2–4]. Perhaps the most extensively studied process involv-
ing NO is related to vascular relaxation, in which variations in the
NO concentration are attributed to decreasing cytosolic Ca2+ levels
[5,6]. NO-induced vascular relaxation occurs by stimulating the
production of guanosine 30,50-cyclic monophosphate (cGMP) via
soluble guanylyl-cyclase (sGC) activation [7] and/or by causing
membrane hyperpolarization via K+ channel activation [8].
Despite the great importance of NO in biological systems, its
pharmacological studies have been limited due to its high reactiv-
ity and short half-life [9,10]. The free radical nature of NO has hin-
dered the understanding of many problems associated with its
diffusion delay or associated with the effect that NO presents on
its action targets [11,12]. One compound commonly used as NO-.
r OA license.delivery agent in pharmacological and clinical studies is the so-
dium nitroprusside salt (SNP) {Na2[Fe(CN)5NO]} [13,14]. However,
SNP is potentially dangerous owing to side reactions involving cya-
nide (CN) release as part of the reduction process [14,15], and this
poses an important limitation to its pharmacological use [16]. In
this context, the development of new molecules that deliver NO
under controlled conditions can be a valuable tool for the under-
standing of its biological mechanism and could constitute a new
class of therapeutic agents [17,18]. Nitrosyl ruthenium complexes
have been postulated as a new class of NO-delivery agents [19]
based on reduction process, tissue-enzymatic action [14–16] or
through light irradiation [20]. Despite the well-established phar-
macological process of these ruthenium species, their stability is
dependent on pH, because their conversion to nitro-ruthenium
species (Eq. (1)) apparently yields a compound that is a less potent
NO-donor agent [21]. This somehow limits the use of these species
in therapeutic evaluations [22].
½RuL5NO3þ þ 2OH * ½RuL5NO2þ þH2O ð1Þ
Until recently, nitrite was considered an end-product of NO
metabolism. However, several studies support evidence that nitrite
metabolism occurs in the tissues and blood to form NO [23]. In fact,
nitrite can be considered the largest intravascular storage pool for
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role of nitrite in the treatment and prevention of cardiovascular
diseases such as hypertension [25]. Several ruthenium-derived
compounds have been synthesized in our laboratory [19]; how-
ever, only the complex cis-[Ru(bpy)2(py)NO2](PF6) (RuBPY) con-
tains nitrite that can be converted to NO.
During physiological and pathological hypoxia, nitrite is con-
verted to NO via reactions with hemoglobin, myoglobin, xanthine
oxidoreductase, and heme- and tiol-containing enzymes, and by
acidic disproportionation [26]. Vasodilatation induced by nitrite
has been reported to occur after infusion of sodium nitrite into
the forearm brachial artery of healthy volunteers, which increased
blood ﬂow and produced substantial vasodilatation [24]. The ni-
trite reductase activity of deoxyhemoglobin is a major mechanism
of NO generation from nitrite [27], and it may be involved in hyp-
oxic vasodilation. As reported by Alzawahra et al. [28] nitrite can
be reduced to NO by heme proteins such as sGC, which in turn
can be inhibited by ODQ. Several new metal complexes have been
studied as a new class of NO donors [29], including nitrosyl ruthe-
nium complexes. Some of these complexes exhibit low toxicity and
are quite soluble in aqueous solutions. Our new nitrite ruthenium
NO donor RuBPY contains nitrite in its molecule, which makes this
NO donor different from others studied in our laboratory [30–32].
Considering the chemical characteristics of the RuBPY complex,
the aim of the present work was to study the effect of this nitrite
ruthenium NO-donor complex as a pro-drug that could release
NO only upon induction. The vasorelaxation induced by this inor-
ganic NO donor was thus studied, and its effects were compared
to those obtained with the well known NO donor SNP.
Materials and methods
Synthesis of cis-[Ru(bpy)2(py)NO2](PF6) (RuBPY)
The RuBPY complex was synthesized as previously reported and
was characterized by UV–Visible spectroscopy as well as cyclic vol-
tammetry experiments [33].
Amperometric determination of NO release from the NO donor
TheNOmeasurementswere performed by using the ISO-NONO-
meter and DUO-18 acquisition board. The sensitivity of this appara-
tus ranges from 1 nM to 20 lM, with a 2 mm sensor, which directly
detects NO by amperometric technique. The setup was calibrated
following a previously reported procedure [34–36]. NO released
from 100 lM RuBPY in Krebs salt solution was measured in the ab-
sence or in the presence of phenylephrine or in the presence of the
aortic ring. All the experiments were performed at room light.
Confocal microscopy
In order to image arterial cross-sections, the rings (100 lm
thick) were placed vertically in a glass slide covered with poly-L-ly-
sine. The tissue was loaded with the ﬂuorescent NO dye, diamino-
ﬂuorescein-2 diacetate (10 lM DAF-2 DA), in the normal Hanks
solution for 40 min at room temperature [37]. After washing, the
segment was placed in a chamber (1 mL in volume) that was
placed on the stage of the confocal scanning laser microscope (Lei-
ca TCS SP2) and viewed from the bottom of the chamber through a
water-immersion objective (63). Images of the aortic ring seg-
ment were sequentially taken every 2 s in Hanks buffer (pH 7.4)
with the following composition (mM): NaCl 145, KCl 5.0, NaH2-
PO4H2O 0.5, MgCl26H2O 1.0, glucose 10.0, CaCl2 1.6, and Hepes
10.0. The cytosolic NO concentration ([NO]c) was assessed by excit-
ing the DAF-2 DA ﬂuorophore with the 488 nm line of an argon ion
laser and measuring the ﬂuorescence at 515 nm. A time-coursesoftware was used to capture images of the cells at intervals of
2 s (xyt) in the Live Data Mode acquisition at 512  512 pixel res-
olution, at 400 Hz. The protocol was designed to measure [NO]c in
denuded slices of rat aorta. [NO]c was measured in the vascular
smooth muscle before and after addition of 3 lM RuBPY in the
presence or absence of 1 lM sGC inhibitor [1H-[1,2,4]oxadiazolo-
[4,3-a]quinoxalin-1-one] (ODQ). By applying the computer soft-
ware of the LSCM, the intensities of intracellular maximum or min-
imum ﬂuorescence were measured. In this way, the difference in
ﬂuorescence intensity (DFI) between the basal spectrum (F0) and
the spectrum recorded after addition of the NO donor (F) reﬂects
the increase in [NO]c, which was calculated by the formula:
DFI = (F  F0). The ﬂuorescence signal used to calculate [NO]c was
measured in a area of aortic smooth muscle tissue and averaged.
Aortic ring preparations
The pharmacological studies were performed in accordance
with the Ethical Animal Committee of the University of São Paulo
(07.1.608.53.8 Campus of Ribeirão Preto).
Male Wistar rats (180–200 g) were killed by decapitation under
anesthesia. The thoracic aorta was quickly removed, dissected free,
and cut into 4 mm-long rings. The endothelium was mechanically
removed by gently rolling the lumen of the vessel on a thin wire.
The aortic rings were placed between two stainless-steel stirrups
and connected to an isometric force transducer (Letica Scientiﬁc
Instruments, Barcelona, Spain), to measure the tension. The rings
were placed in a 10 mL organ chamber containing Krebs solution
with the following composition (mM): NaCl 130, KCl 4.7, KH2PO4
1.2,MgSO4 1.2, NaHCO3 14.9, glucose 5.5, andCaCl2 1.6. The solution
was maintained at pH 7.4 and gassed with 95% O2 and 5% CO2, at
37 C. After an equilibration period of 60 min., under resting tension
of 1.5 g, the aortic rings were continuously stimulated with 0.1 lM
phenylephrine, which is the concentration that produced half-max-
imal contraction (EC50) until reproducible contractile responses
were obtained. All experiments were performed on endothelium-
denuded aortic rings. The absence of endothelium was conﬁrmed
by the lack of relaxation response to 1 lMacetylcholine in the pres-
ence of contractile tone inducedby phenylephrine. Since our studies
require endothelium-denuded aortas, the rings were discharged if
therewas any degree of relaxation to acetylcholine, in order to avoid
possible inﬂuence from endothelial factors. After the equilibration
period, speciﬁc protocols were performed in rat aortic rings.
Experimental protocols
Relaxation induced by RuBPY and SNP in arteries pre-contracted with
phenylephrine
Aortic rings were pre-contracted with phenylephrine (PE,
0.1 lM). When the contraction to phenylephrine had reached a
plateau, RuBPY (3 nM–5 lM) or SNP (0.1 nM–0.1 lM) was cumula-
tively added.
Time-course for the relaxation induced by RuBPY and SNP
In order to study the kinetics of the vasorelaxation effect, the
NO donors were added to the organ chamber when a stable con-
traction in response to 0.1 lM phenylephrine was achieved. The
NO donors were added at the concentration that induced maxi-
mum relaxation, i.e., 3 lM RuBPY or 0.1 lM SNP. The time-course
for the relaxation induced by these compounds was evaluated.
Relaxation induced by RuBPY and SNP in arteries pre-contracted with
60 mM KCl
Aortic rings were pre-contracted with highly concentrated KCl
solution (60 mM), and cumulative concentration–response curves
were constructed for RuBPY (3 nM–5 lM) or SNP (0.1 nM–0.1 lM).
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induced by RuBPY and SNP
In order to verify whether the vasodilatation induced by the
new NO donor RuBPY is due to guanylyl-cyclase activation, the
selective sGC inhibitor ODQ (1 lM) was added 30 min before the
addition of phenylephrine (0.1 lM). Subsequently, cumulative
concentration–response curves for RuBPY and SNP were con-
structed in the presence of ODQ.
Effect of the inhibition of phosphodiesterase on the relaxation induced
by RuBPY and SNP
In order to verify whether cGMP is involved in the relaxation of
aortic rings by RuBPY and SNP, the selective inhibitor of type V
phosphodiesterase (PDE), dipyridamole (1 lM) was added 30 min
before the addition of phenylephrine (0.1 lM). Subsequently,
cumulative concentration–response curves for RuBPY
(3 nM–5 lM) or SNP (0.1 nM–0.1 lM) were constructed in the
presence of dipyridamole.
Drugs and solutions
Acetylcholine, phenylephrine, ODQ, sodium nitroprusside
(SNP), dipyridamole and DAF-2 DA were purchased from Sigma
Chemical Co. (St. Louis, MO-USA). Acetylcholine, SNP, and phenyl-
ephrine were diluted in deionized water. RuBPY solutions were
prepared in pH 7.4 phosphate buffer (1 mM). ODQ and dipyridam-
ole were diluted in dimethylsulfoxide. DAF-2 DA was prepared in
Hanks physiological solution.
Data and statistical analysis
Relaxation responses to the NO donor were measured from the
plateau of the phenylephrine contraction and were expressed as
percent reversal of the phenylephrine pre-contraction. Individual
relaxation curves were ﬁtted to a sigmoidal logistic equation
(Graphpad Prism 3.0); pD2 values (pEC50) were calculated and ex-
pressed as log [M]. The maximum effect (Emax) was considered as
the maximal amplitude response reached in the concentration-ef-
fect curves for the relaxant agent. In each set of experiments, n
indicates the number of studied rats. Differences between mean
pD2 and Emax values were both assessed by one-way analysis of
variance (ANOVA) followed by a Newman–Keuls post-hoc test. Un-
paired student’s t test was used to analyze the microscopy data.
Results are expressed as mean ± SEM, and statistical signiﬁcance
was accepted at a level of P < 0.05.
Results
Determination of NO release from the NO donor
According to the electronic spectroscopy analysis, the nitrite
ruthenium complex RuBPY is stable in aqueous solution, at room
temperature, for at least 10 days. Similarly, RuBPY does not exhibit
any appreciable photoreactivity under visible light irradiation.
However, chronoamperograms performed with RuBPY in physio-
logical solution in the presence of aortic tissue, using an NO-sensor,
revealed a typical pattern derived from an NO-donor agent (Fig. 1),
which was not observed when the experiment was developed with
the vehicle only, the NO donor only, or the NO donor in the pres-
ence of phenylephrine.
Confocal microscopy
NO measurement in the cell milieu was also accomplished by
confocal microscopy (Fig. 2). Nitric oxide was quantiﬁed by mea-suring the ﬂuorescence intensity (FI) by using ﬂuorescent dye
DAF-2 DA that intracellularly is converted to DAF-2T. The cytosolic
NO concentration ([NO]c) in the vascular smooth muscle of aortic
rings was obtained in the absence of the complex and after addi-
tion of RuBPY. In the latter case, the basal [NO]C was signiﬁcantly
increased in DFI: 1645.14 ± 388.30 (n = 5). As for the aortic rings
pre-incubated with ODQ, the ﬂuorescence was lower DFI:
366.88 ± 120.3 (n = 7, P < 0.01) than that achieved in the aortic tis-
sue in the absence of ODQ, as depicted in Fig. 2C.
Relaxation induced by RuBPY and SNP in arteries pre-contracted with
phenylephrine
The relaxations inducedby bothNOdonors RuBPYand SNP in de-
nuded rat aortas pre-contracted with 0.1 lM phenylephrine were
concentration-dependent. Although the maximum effect (Emax)
was similar for SNP (101.2 ± 2.8%, n = 5) and RuBPY (104.4 ± 1.1%,
n = 5), the potency of SNP (pD2: 8.25 ± 0.12, n = 5) was greater than
the potency of RuBPY (pD2: 6.54 ± 0.07,n = 5, P < 0.001)with respect
to induction of aortic rings relaxation (Fig. 3).
Time-course for the relaxation induced by RuBPY and SNP
As shown in Fig. 4, the use of NO donor concentrations that
yield maximum relaxation demonstrates that the SNP and RuBPY
complexes present similar time-course, with maximum relaxation
occurring at 210 and 240 s, respectively.
Relaxation induced by RuBPY and SNP in arteries pre-contracted with
60 mM KCl
Vascular reactivity studies revealed that the complex does not
require chemical reduction to release NO and promote vasodilata-
tion. In aortic rings pre-contracted with 60 mM KCl, the maximum
effect was lower (60.2 ± 3.5%, n = 6, P < 0.001) than that obtained in
phenylephrine pre-contracted arteries (104.9 ± 1.1%, n = 5) (Fig. 5).
Similar results were found for SNP that had its vasodilatation re-
duced from 101.2 ± 2.8% to 44.0 ± 1.8%; n = 5 (P < 0.001).
Effect of the soluble guanylyl-cyclase inhibitor ODQ on the relaxation
induced by RuBPY and SNP
Our studies also evidenced that NO released from the RuBPY
complex induces vasodilatation by activation of sGC. Indeed, the
selective sGC inhibitor ODQ reduced the maximum relaxation of
the compound RuBPY from 104.4 ± 1.1% to 38.0 ± 3.6% (n = 8, P
< 0.001), as shown in Fig. 6. Similar results were found for SNP
where the vasodilatation was reduced from 101.2 ± 2.8% to
29.3 ± 2.6%; n = 5 (P < 0.001) in the presence of ODQ.
Effect of inhibition of phosphodiesterase (PDE) on the relaxation
induced by RuBPY and SNP
Vascular reactivity studies revealed that the vasodilatation in-
duced by RuBPY was potentiated when PDE-V was inhibited with
dipyridamole. The pD2 values increased from 6.54 ± 0.07 (n = 5)
to 6.99 ± 0.09, (n = 5), P < 0.05 (Fig. 7). We also found similar results
for SNP that had higher potency in the presence of PDE inhibitor
(pD2: from 8.25 ± 0.12 (n = 5) to 8.96 ± 0.15 (n = 6), P < 0.001.
Discussion
Although some nitrosyl ruthenium complexes have been
reported to be NO-delivery agents, numerous species are unstable
in physiological conditions or give rise to side-reactions that lead
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Fig. 1. Amperometric measurement of NO released in Krebs solution in the absence of the complex RuBPY (vehicle), in the presence of the complex RuBPY (RuBPY 100 lM), in
the presence of phenylephrine (RuBPY 100 lM + PE), or in the presence of RuBPY and the aortic ring (RuBPY 100 lM + tissue). All experiments were performed in room light.
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Fig. 2. Fluorescent image of cytosolic concentration of nitric oxide ([NO]c) in a
representative slice of rat aorta preloaded with DAF-2 DA (10 lM) and stimulated
with RuBPY (3 lM). Fluorescence of DAF-2 DA was recorded before (A) and after (B)
the addition of RuBPY. Average ﬂuorescence intensity (DFI) of [NO]c in denuded
endothelium rat aortic slices loaded with DAF-2 DA after addition of RuBPY (3 lM)
in aortic rings with or without ODQ (C). Data are mean ± SEM of experiments
performed on preparations obtained from different animals. ⁄ Difference between
the values in aortic rings with or without ODQ (P < 0.01).
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Fig. 3. Relaxation induced by RuBPY and by SNP on denuded endothelium rat aortic
rings pre-contracted with 0.1 lM phenylephrine (PE). Responses to RuBPY (n = 5) or
SNP (n = 5) are represented as the percentage of the reversal pre-contraction with
PE. Data are mean ± SEM of experiments performed on preparations obtained from
different animals. ⁄ P < 0.001 for pD2 values RuBPY vs. SNP.
Fig. 4. Time-course for RuBPY- and sodium nitroprusside (SNP)-induced relaxation.
Denuded aortic rings were pre-contracted with 0.1 lM phenylephrine, and 3 lM
RuBPY (n = 7) or 0.1 lM SNP (n = 4) was added. Data are mean ± SEM of
experiments performed on preparations obtained from different animals.
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that RuBPY can function as an NO-delivery agent spontaneously
after crossing the membrane barrier. On the basis of electronic
spectroscopy analysis, the nitrite ruthenium species is stable for
a long period in aqueous solution, at physiological pH. In contrast
to other nitrosyl complexes previously studied in our laboratory
RuBPY does not release NO under visible light irradiation or by a
reducing electrolytic process.
The investigation of the induced NO-releasing pathway was
supported by in situ NO detection when an aqueous phosphate buf-fer solution of RuBPY was submitted to the action of phenylephrine
in the presence of the aortic tissue or room light. The increase in
current, which is proportional to the NO concentration, is negligi-
ble. Nevertheless, in the presence of the aortic tissue, NO is re-
leased from RuBPY with a typical pattern of NO release (Fig. 1).
Fig. 5. Effect of RuBPY or SNP on rat aortic rings pre-contracted with phenylephrine
or KCl. The arteries were pre-contracted with 0.1 lM phenylephrine (PE) or 60 mM
KCl, and RuBPY or SNP were cumulatively added. Data are mean ± SEM of
experiments performed on preparations obtained from different animals.
⁄ P < 0.001, ⁄⁄ P < 0.001 for pD2 and Emax values, respectively, for PE vs. KCl.
Fig. 6. Effect of ODQ on the relaxation induced by RuBPY or SNP on denuded rat
aortic rings. The arteries were pre-contracted with 0.1 lM phenylephrine in the
absence or in the presence of 1 lM ODQ. Data are mean ± SEM of experiments
performed on preparations obtained from different animals. ⁄⁄ P < 0.001 for Emax
values for ODQ vs. RuBPY or SNP.
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Fig. 7. Effect of phosphodiesterase inhibition on the relaxation induced by RuBPY or
SNP in rat aortic rings. The arteries were pre-contracted with 0.1 lM phenylephrine
in the absence or in the presence of 1 lM dipyridamole (DIP). Data are mean ± SEM
of experiments performed on preparations obtained from different ani-
mals.⁄ P < 0.001 for pD2 values for SNP + DIP vs. SNP, ⁄⁄ P < 0.05 for pD2 values for
RuBPY + DIP vs. RuBPY.
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reduced to deliver NO, because NO is not released in the presence
of the reducing agent phenylephrine. On the other hand, NO
release is tissue-dependent. These data differ from results reported
for other ruthenium compounds capable of donating NO, which
only deliver NO upon stimulation [40]. In the present study, the
NO concentration in the smooth muscle of aortic rings was also
determined by using the NO sensitive dye, namely DAF-2 DA. This
dye reacts with N2O3 present in the cell cytosol. The formation of
N2O3 requires two molecules of NO. Therefore, the stoichiometry
of the reaction between DAF-2DA and NO is 1:2, which means thatDAF does not directly react with NO, but it reacts with the oxidized
form of NO [41]. It was observed that the NO concentration is sig-
niﬁcantly enhanced after RuBPY addition. Considering that NO was
measured in denuded aortic rings, the enhanced ﬂuorescence from
the bound DAF can be attributed to NO release from RuBPY. In the
same experiment, it was demonstrated that in presence of a sGC
inhibitor ODQ, the ﬂuorescence of the dye was lower than that
measured in the preparation without ODQ. These results suggest
that enzymes that can be inhibited by ODQ as the soluble gua-
nylyl-cyclase, are responsible for conversion of nitrite present in
the compound to nitric oxide [28].
The new NO donor RuBPY induces relaxation in aortic rings pre-
contracted with phenylephrine in a concentration-dependent
manner, although its potency is lower than that of SNP. Thus, a
higher concentration of RuBPY was necessary to induce 50% of
maximum effect as compared to SNP. These results are in accor-
dance to Bonaventura et al. [32] that have reported a higher po-
tency of SNP as compared to another nitrosyl complex. SNP is
well-known to be a rapid and efﬁcient nitrovasodilator compound
[42] that is therapeutically used in hypertensive emergencies. SNP
is thought to exert its vasodilator action, at least in part, by NO re-
lease into the vascular smooth muscle cell. In our experiments, the
maximum relaxation was reached with 0.1 lM SNP and 3 lM RuB-
PY (Fig. 3). However, both NO donors presented similar efﬁcacy in
relaxing the rat aorta. Similar experiments were performed by
using sodium nitrite [28] and, in this work, the authors used
2 mM NO donor to reach 100% vasodilatation, which is 1000 times
more concentrated than the RuBPY concentrations reported here to
have equivalent effects. If similar vasorelaxation mechanisms are
proposed for both nitrite species, it can be inferred that the nitrite
ruthenium complex favors the mechanism involved in NO
generation.
The time required for achievement of the complete concentra-
tion–effect curve for relaxation with RuBPY is not signiﬁcantly dif-
ferent from that found in the case of SNP once the concentrations
were adjusted in account for the difference of efﬁcacy. In the pul-
monary arteries of male piglets, Lopez-Lopez et al. [42] have re-
ported that the time-course of relaxation to a single
concentration of SNP (3 lM) was 220 s. The differences between
our results and those observed by Lopez-Lopez et al. [42] are insig-
niﬁcant but the concentrations of SNP used were different, it may
be related to vascular bed or animal species.
In the present study, we have compared the cellular mecha-
nisms of vasodilatation induced by our compound and with SNP.
To investigate whether the ruthenium complex requires chemical
reduction to promotes vasodilatation, we have constructed con-
centration–response curves for RuBPY in the absence of the reduc-
ing agent phenylephrine. The preparations were pre-contracted
with KCl, in which the contractile response is not mediated by
receptors but by cell membrane depolarization, thereby resulting
in the opening of voltage-dependent calcium channels [43].
Since the relaxation induced by RuBPY is diminished but not
abolished by addition of a high concentration of KCl to the extra-
cellular medium, the hypothesis that K+ channel activation is
important for RuBPY relaxation could be proposed, but this is not
the only mechanism involved in the rat aorta relaxation induced
by this NO donor. We have found similar results to SNP that had
its relaxation decreased but not abolished. Our results demon-
strated that SNP can release NO by other ways else chemical reduc-
tion by photochemical release and decomposition in presence of
vascular tissue as reported by Bates et al. [14].
NO induces vascular smooth muscle relaxation through the
activation of sGC, hence converting GTP to cGMP, which acts as a
second messenger activating PKG. The latter, in turn, phosphory-
lates various proteins, producing vasorelaxation [44]. The increase
in cGMP levels and the consequent activation of PKG reduces cyto-
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channel activation and inhibition of L-type Ca+2 channels [45] or
direct activation of K+ channels by NO [8]. On the basis of these
mechanisms activated by NO, another purpose of the present study
was to characterize the vascular effects of this NO donor by using
pharmacological tools like sGC inhibitors.
ODQ, a selective inhibitor of sGC [46], was employed for veriﬁca-
tion of the role of this enzyme in the relaxation cascade induced by
RuBPY. The inhibitory effect of ODQ is due to changes in the oxida-
tion state of the heme moiety without adverse effects on the
catalytic activity of the enzyme. Although ODQ has been reported
to interfere with heme-protein-dependent process [47], it remains
the most selective and potent inhibitor available for soluble gua-
nylyl-cyclase. Sensitivity toward ODQ inhibition of vascular relaxa-
tion would indicate a predominant mechanism of heme site-
mediated activation of sGC, whereas resistance toward ODQ would
suggest the possible presence of alternative mechanisms of vasore-
laxation. Our results have shown that the relaxation induced by
RuBPY or SNP are partially inhibited by ODQ. These results suggest
that these NO donors can elicit vascular relaxation, at least in part,
through a secondary pathway that is independent of the activation
of the heme site of sGC.
In the present study we have observed the effect of type 5
cGMP-PDE inhibition on the vasodilatation induced by RuBPY
and SNP. The predominant PDE isoenzymes present in human
smooth muscle and endothelial cells are PDE1 and PDE5, and dipy-
ridamole selectively inhibits the latter. Dipyridamole, therefore,
could act by potentiating the actions of those mediators that work
through cGMP, such as nitric oxide [48]. In the relaxation response
induced by RuBPY or SNP, dipyridamole produced a leftward shift
of the concentration–response curve. These results provide evi-
dence for the effect of cGMP in the vasodilatation induced by the
NO donors RuBPY and SNP.
Taken together, the present ﬁndings demonstrate that the new
complex RuBPY has its nitrite converted into NO, and that this pro-
cess appears to be catalyzed by soluble guanylyl-cyclase enzyme
sensitive to ODQ. The RuBPY complex induces vascular relaxation
that is as fast as that promoted by SNP. Our results demonstrated
that the mechanisms of relaxation by RuBPY are similar to SNP
with high participation of sGC-cGMP.
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